Abstract
Doxil® is a pegylated liposome formulation of the anthracycline doxorubicin. To better explain observed differences in the toxicity of Doxil® and free doxorubicin in solution, the intracellular metabolism of the formulations after treatment in CCRF-CEM and CEM/C2 human leukemia cell lines was investigated. Using micellar electrokinetic capillary chromatography with laser-induced fluorescence detection, with a 63 zepto (10-21) mole doxorubicin limit of detection, five common metabolites and doxorubicin were detected upon treatment with both of these drug delivery systems. Two unique metabolites appeared with the Doxil® and two unique metabolites appeared with the free doxorubicin delivery systems. For common metabolites, the relative amount of metabolite generated from Doxil® was approximately 10 times higher than for free doxorubicin.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 115-122 |
| Number of pages | 8 |
| Journal | Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences |
| Volume | 829 |
| Issue number | 1-2 |
| DOIs | |
| State | Published - Dec 27 2005 |
Bibliographical note
Funding Information:This work has been supported by NIH R01-GM61969. We also wish to thank Dr. Antonio Suarato, Pharmacia, for his kind donation of doxorubicin.
Keywords
- Capillary
- Doxil
- Doxorubicin
- Electrophoresis
- Laser-induced fluorescence
- Liposome
- Metabolism
- Micellar electrokinetic capillary chromatography
